Premium
Early Human Screening of Medications to Treat Drug Addiction: Novel Paradigms and the Relevance of Pharmacogenetics
Author(s) -
Perkins KA,
Lerman C
Publication year - 2011
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2010.254
Subject(s) - clinical pharmacology , pharmacogenetics , medicine , addiction , drug , clinical trial , pharmacodynamics , pharmacology , adverse effect , drug reaction , intensive care medicine , pharmacokinetics , psychiatry , biology , biochemistry , genotype , gene
Initial screening of medications for efficacy in treating drug dependence may be accomplished more efficiently by using novel approaches that combine the practical advantages of within‐subject laboratory studies with the clinical validity provided by clinical trials. A priori selection of functional gene variants associated with the pharmacokinetic or pharmacodynamic effects of a medication may aid this effort by controlling for individual variability as to clinical response or adverse effects; however, there are limitations to this approach, and these should be carefully considered. Clinical Pharmacology & Therapeutics (2011) 89 3, 460–463. doi: 10.1038/clpt.2010.254